Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alflutinib in Advanced T790M+ NSCLC
NCT03127449Phase 2Terminated
- Sponsor
- Allist Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- May 2021
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Jun 2017; status: terminated.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03127449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127449.